Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. This trial will compare two effective therapies, allopurinol and febuxostat, to ...

Background The Febuxostat versus Allopurinol Streamlined Trial (FAST) is a prospective, randomised, open-label, blinded endpoint trial comparing the cardiovascular safety of allopurinol and febuxostat ...

Objectives To update comparative CV safety of febuxostat versus allopurinol among patients with gout Methods Using the 2011-2019 Korea National Health Insurance database, we conducted a cohort study ...

Febuxostat Open-label Clinical Trial of Urate-lowering Efficacy and Safety Adverse events were ... febuxostat 120-mg, and allopurinol groups, respectively. Serious adverse events were reported ...

Less than 50% reported following initial recommended dosages for allopurinol or febuxostat. Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout ...

The Food and Drug Administration (FDA) had cited some safety concerns when it approved lesinurad ... “These patients would consider combining allopurinol plus febuxostat, pegloticase infusions, or ...

This study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad in combination with febuxostat in adults with gout. Methods The phase IIa, open-label, multicentre study randomised ...

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impair ...